In an ambitious bid to prevent the spread of HIV, several prominent global health organizations will provide backing for two generic manufacturers to produce and distribute a low-cost version of a groundbreaking Gilead Sciences drug in dozens of poor countries.

The arrangements call for Dr. Reddy’s Laboratories and Hetero — two of the largest purveyors of generic medicines — to make versions of lenacapavir available at $40 per person a year in 120 low- and middle-income countries starting in early 2027. The effort is being spearheaded by Unitaid, the Clinton Health Access Initiative, and the Gates Foundation, which will offer financing and technical support.

The Gilead drug, an injectable medicine sold as Yeztugo, has caused a stir because study data showed a single set of injections eve

See Full Page